Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 8/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | KIT | P10721 | 3/20 | 0.37 |
| ▸ | LANCL2 | Q9NS86 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18918679 | 0.89 | ULK1 (0.49) | ULK1KITLANCL2USP2CYP1A2 | |
| SCHEMBL18932432 | 0.89 | ULK1 (0.49) | ULK1KITLANCL2USP2CYP1A2 | |
| SCHEMBL18918809 | 0.88 | ULK1 (0.49) | ULK1KITLANCL2USP2CYP1A2 | |
| SCHEMBL18932436 | 0.88 | ULK1 (0.48) | ULK1KITLANCL2USP2CYP1A2 | |
| SCHEMBL18944196 | 0.87 | ULK1 (0.46) | ULK1KITLANCL2USP2CYP1A2 | |
| SCHEMBL18918802 | 0.86 | ULK1 (0.50) | ULK1KITLANCL2USP2CYP1A2 | |
| SCHEMBL18944109 | 0.85 | ULK1 (0.47) | ULK1KITLANCL2USP2CYP1A2 | |
| SCHEMBL18932435 | 0.85 | ULK1 (0.49) | ULK1KITLANCL2USP2CYP1A2 | |
| SCHEMBL18918803 | 0.85 | ULK1 (0.46) | ULK1KITLANCL2USP2CYP1A2 | |
| SCHEMBL18918898 | 0.84 | ULK1 (0.45) | ULK1KITLANCL2USP2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170158690-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158690-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K11, MAP3K13, WEE2 | ULK1 495/4885CNR2 1697/4885KIT 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.